Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

albert_bourla2019_300x170_1

Pfizer CEO Albert Bourla to Succeed Ian Read as Executive Chairman

September 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Pfizer’s executive chairman Ian Read, is to be succeeded by CEO Albert Bourla with a date to start the post …
Appointment
shutterstock

The world needs a better plan for cancer survival by 2030

September 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Roche, UN General Assembly, United Nations, feature, opinion, pharma

Beginning on 24 September, the UN will convene in New York for its annual General Assermbly. Dr Christian Rommel, Roche´s …
Feature
astrazeneca_building_white

AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

September 30, 2019 Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …
News
merck-keytruda

MSD’s Keytruda meets primary endpoint in triple-negative breast cancer

September 30, 2019 Sales and Marketing

MSD have announced results from its Phase 3, KEYNOTE-522 trial that pathological complete response (pCR) in patients with early triple-negative …
News

Roche secures US paediatric approval for Rituxan in two rare forms of vasculitis

September 30, 2019 Sales and Marketing MabThera, Rituxan, Roche, pharma, vasculitis

Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination …
News

Novartis reports positive Phase 3 PALLADIUM results in uncontrolled asthma

September 30, 2019 Sales and Marketing

Novartis has announced that its investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate) was superior to mometasone furoate …
News
lynparza

AZ and Merck’s ovarian cancer combo improves progression-free survival

September 30, 2019 Sales and Marketing

AstraZeneca and Merck have announced that their combination treatment for newly diagnosed ovarian cancer significantly improved progression free survival. The …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 27, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten

Another week comes to a close, and it’s time to review the biggest stories of the week. Check out the …
News
abbvie_0

AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients

September 27, 2019 Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma

The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …
News
darzalex-product-shot---100mg-vial-2-hr

FDA approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

September 27, 2019 Medical Communications, Sales and Marketing FDA, Genmab, darzalex, pharma

Genmab’s CD38 inhibitor Darzalex (daratumumab) has been awarded marketing authorisation from the FDA in combination with bortezomib, thalidomide and dexamethasone …
News

NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland

September 26, 2019 Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
News
takeda_world

Takeda’s investigational therapy shows promise as cytomegalovirus treatment

September 25, 2019 Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma

New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …
News
opdivo_1_1

EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma

September 25, 2019 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …
News
celltrion1

Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation

September 24, 2019 Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …
News

Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy

September 24, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma

Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025